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Radiopharmaceuticals, drugs consisting of a radionuclide, are very useful in 
both the diagnostic and therapeutic treatment of cancer. The 
radiopharmaceuticals that were researched are composed of Re radioisotopes 
(Re-186; Re-188), which are very effective in cell destruction. The Re 
radioisotope must be coordinated to a tetradentate ligand, which would be 
linked to a biological targeting molecule. The biological targeting molecule 
is used to guide the radionuclide through the body to the cancer cells. Once 
it is at the cancer, the radioisotope can then be used to eliminate the 
cancer. The most challenging aspect of synthesizing a useful 
radiopharmaceutical is making a drug that will release limited amounts of 
radiation to other parts of the body before the radionuclide can reach the 
cancer cells. Therefore, it is extremely important for the radiometal to form 
a kinetically inert complex so that it will not cause extreme damage to 
healthy body parts. The primary goal of this study was to synthesize a stable 
Re(III) complex that could be attached to a biological targeting molecule. 
First, the tetradentate ligand sal2phen was synthesized. This reaction 
resulted in a high yield of an orange powder. Next, Re was reacted with the 
sal2phen to form the complex [Re(V)OCl(sal2phen)], which was fully 
characterized. This Re complex was then reacted with triphenylphosphine with 
the intent to make a Re(III) metal center, which is more kinetically inert 
than the Re(V) metal center. Characterization methods used included IR, 
Proton NMR, and 31P NMR. 
 
